I期临床试验-话题@MedSci

#I期临床试验#

226篇内容 | 3887人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2088847, encodeId=19a8208884e3b, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=DB102（Enzastaurin）治疗初治胶质母细胞瘤（GBM）：已启动III期临床试验, objectType=article, longId=205630, objectId=ad3c205630c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad3c205630c9, replyNumber=0, likeNumber=81, createdTime=2021-11-10, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad3c205630c9, moduleTitle=DB102（Enzastaurin）治疗初治胶质母细胞瘤（GBM）：已启动III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad3c205630c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088856, encodeId=e39920888562e, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=NEJM：罗氏旗下基因泰克的类风湿药物Actemra在COVID-19 III期临床试验中未能达到其主要终点, objectType=article, longId=208482, objectId=a52b208482ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a52b208482ca, replyNumber=0, likeNumber=88, createdTime=2021-11-17, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a52b208482ca, moduleTitle=NEJM：罗氏旗下基因泰克的类风湿药物Actemra在COVID-19 III期临床试验中未能达到其主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a52b208482ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088862, encodeId=234d20888626c, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=2021年4月19日全球新冠肺炎（COVID-19）疫情简报，确诊超1亿4198万，国内保护力更强的灭活疫苗和mRNA疫苗均即将进入III期临床试验, objectType=article, longId=210178, objectId=c5462101e853, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5462101e853, replyNumber=0, likeNumber=56, createdTime=2022-01-29, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5462101e853, moduleTitle=2021年4月19日全球新冠肺炎（COVID-19）疫情简报，确诊超1亿4198万，国内保护力更强的灭活疫苗和mRNA疫苗均即将进入III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5462101e853)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088857, encodeId=2ccd208885ecb, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=长效抗体GSK3511294控制重度哮喘，III期临床试验即将开始, objectType=article, longId=208679, objectId=00752086e9b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00752086e9b6, replyNumber=0, likeNumber=140, createdTime=2021-10-05, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00752086e9b6, moduleTitle=长效抗体GSK3511294控制重度哮喘，III期临床试验即将开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00752086e9b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088838, encodeId=f49220888381a, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=北京科兴生物的新冠COVID-19疫苗在巴西的III期临床试验被暂停, objectType=article, longId=203249, objectId=a99020324958, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a99020324958, replyNumber=0, likeNumber=77, createdTime=2021-09-13, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a99020324958, moduleTitle=北京科兴生物的新冠COVID-19疫苗在巴西的III期临床试验被暂停, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a99020324958)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088870, encodeId=dd5620888e095, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=巴西ANVISA批准Proxalutamide用于治疗住院COVID-19患者的III期临床试验, objectType=article, longId=217765, objectId=135021e76506, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=135021e76506, replyNumber=0, likeNumber=58, createdTime=2021-10-29, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=135021e76506, moduleTitle=巴西ANVISA批准Proxalutamide用于治疗住院COVID-19患者的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=135021e76506)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088860, encodeId=67ad20888606b, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=FP-025治疗COVID-19相关的ARDS，II/III期临床试验已正式开始, objectType=article, longId=209159, objectId=3dc92091590c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3dc92091590c, replyNumber=0, likeNumber=58, createdTime=2021-07-06, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3dc92091590c, moduleTitle=FP-025治疗COVID-19相关的ARDS，II/III期临床试验已正式开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3dc92091590c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088867, encodeId=8a4f208886e8c, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Noxopharm的TBK1抑制剂idronoxil I期临床试验显示新冠肺炎患者有抗炎应答, objectType=article, longId=216356, objectId=c32b21635692, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c32b21635692, replyNumber=0, likeNumber=91, createdTime=2022-04-14, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c32b21635692, moduleTitle=Noxopharm的TBK1抑制剂idronoxil I期临床试验显示新冠肺炎患者有抗炎应答, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c32b21635692)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088846, encodeId=35f32088846a9, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=合成生物药物可利霉素（Carrimycin）治疗COVID-19：FDA已允许开展III期临床试验, objectType=article, longId=205036, objectId=8f5c20503649, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f5c20503649, replyNumber=0, likeNumber=112, createdTime=2021-05-11, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f5c20503649, moduleTitle=合成生物药物可利霉素（Carrimycin）治疗COVID-19：FDA已允许开展III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f5c20503649)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088854, encodeId=765d208885493, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=英国批准Aplidin（plitidepsin）治疗COVID-19的III期临床试验, objectType=article, longId=207295, objectId=aa7320e295db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa7320e295db, replyNumber=0, likeNumber=65, createdTime=2021-03-21, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa7320e295db, moduleTitle=英国批准Aplidin（plitidepsin）治疗COVID-19的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa7320e295db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088844, encodeId=4b5b20888442d, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Mithra宣布Donesta治疗更年期血管舒缩症状（VMS）的III期临床试验已取得积极结果, objectType=article, longId=204701, objectId=9ebf204e014c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ebf204e014c, replyNumber=0, likeNumber=55, createdTime=2020-12-26, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ebf204e014c, moduleTitle=Mithra宣布Donesta治疗更年期血管舒缩症状（VMS）的III期临床试验已取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ebf204e014c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088866, encodeId=ae952088866d4, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=科济药业发布2021年中期业绩自主研发 CAR-T候选品进入海外关键II期临床试验, objectType=article, longId=216260, objectId=c3532162608a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3532162608a, replyNumber=0, likeNumber=69, createdTime=2022-03-02, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3532162608a, moduleTitle=科济药业发布2021年中期业绩自主研发 CAR-T候选品进入海外关键II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3532162608a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088843, encodeId=bad52088843a9, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=TC-210治疗难治性间皮素阳性实体瘤：I/II期临床试验取得积极结果, objectType=article, longId=204514, objectId=6550204514fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6550204514fe, replyNumber=0, likeNumber=87, createdTime=2021-11-03, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6550204514fe, moduleTitle=TC-210治疗难治性间皮素阳性实体瘤：I/II期临床试验取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6550204514fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088832, encodeId=b5462088832e8, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Entos Pharmaceuticals已获进行COVID-19 DNA疫苗I期临床试验的资金支持, objectType=article, longId=202450, objectId=e82920245051, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e82920245051, replyNumber=0, likeNumber=64, createdTime=2021-02-23, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e82920245051, moduleTitle=Entos Pharmaceuticals已获进行COVID-19 DNA疫苗I期临床试验的资金支持, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e82920245051)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088850, encodeId=c8a82088850e9, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Brilacidin治疗COVID-19的II期临床试验，计划于下周开始, objectType=article, longId=206528, objectId=f96e206528c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f96e206528c2, replyNumber=0, likeNumber=57, createdTime=2021-04-10, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f96e206528c2, moduleTitle=Brilacidin治疗COVID-19的II期临床试验，计划于下周开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f96e206528c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088845, encodeId=6f9c2088845ec, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=中国艾滋病疫苗或明年开启III期临床试验，有望突破HIV困局, objectType=article, longId=204745, objectId=8fbc204e4566, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fbc204e4566, replyNumber=0, likeNumber=138, createdTime=2020-12-31, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fbc204e4566, moduleTitle=中国艾滋病疫苗或明年开启III期临床试验，有望突破HIV困局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8fbc204e4566)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088827, encodeId=5217208882e76, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=强生新冠疫苗进入III期临床试验，大选前疫苗出炉有望吗？, objectType=article, longId=201486, objectId=14fc201486bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14fc201486bd, replyNumber=0, likeNumber=59, createdTime=2021-02-26, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14fc201486bd, moduleTitle=强生新冠疫苗进入III期临床试验，大选前疫苗出炉有望吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14fc201486bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088837, encodeId=d831208883e97, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=FDA允许开展Silmitasertib治疗COVID-19患者的II期临床试验, objectType=article, longId=203072, objectId=4a132030e2bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a132030e2bd, replyNumber=0, likeNumber=56, createdTime=2020-11-18, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a132030e2bd, moduleTitle=FDA允许开展Silmitasertib治疗COVID-19患者的II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a132030e2bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088852, encodeId=222b2088852ff, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=NEJM：每日一次Relugolix联合疗法治疗子宫肌瘤的III期临床试验, objectType=article, longId=207256, objectId=1d0f20e25662, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d0f20e25662, replyNumber=0, likeNumber=59, createdTime=2021-12-27, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d0f20e25662, moduleTitle=NEJM：每日一次Relugolix联合疗法治疗子宫肌瘤的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d0f20e25662)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088818, encodeId=e68e20888187b, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=CheckMate-743是且**证明一线免疫治疗能够改善恶性胸膜间皮瘤患者生存获益的III期临床试验, objectType=article, longId=199161, objectId=739d19916169, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=739d19916169, replyNumber=0, likeNumber=115, createdTime=2021-04-03, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=739d19916169, moduleTitle=CheckMate-743是且**证明一线免疫治疗能够改善恶性胸膜间皮瘤患者生存获益的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=739d19916169)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

I期临床试验

2020-05-29

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

DB102（Enzastaurin）治疗初治胶质母细胞瘤（GBM）：已启动III期临床试验

2021-11-10

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

NEJM：罗氏旗下基因泰克的类风湿药物Actemra在COVID-19 III期临床试验中未能达到其主要终点

2021-11-17

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

2021年4月19日全球新冠肺炎（COVID-19）疫情简报，确诊超1亿4198万，国内保护力更强的灭活疫苗和mRNA疫苗均即将进入III期临床试验

2022-01-29

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

长效抗体GSK3511294控制重度哮喘，III期临床试验即将开始

2021-10-05

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

北京科兴生物的新冠COVID-19疫苗在巴西的III期临床试验被暂停

2021-09-13

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

巴西ANVISA批准Proxalutamide用于治疗住院COVID-19患者的III期临床试验

2021-10-29

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

FP-025治疗COVID-19相关的ARDS，II/III期临床试验已正式开始

2021-07-06

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Noxopharm的TBK1抑制剂idronoxil I期临床试验显示新冠肺炎患者有抗炎应答

2022-04-14

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

合成生物药物可利霉素（Carrimycin）治疗COVID-19：FDA已允许开展III期临床试验

2021-05-11

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

英国批准Aplidin（plitidepsin）治疗COVID-19的III期临床试验

2021-03-21

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Mithra宣布Donesta治疗更年期血管舒缩症状（VMS）的III期临床试验已取得积极结果

2020-12-26

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

科济药业发布2021年中期业绩自主研发 CAR-T候选品进入海外关键II期临床试验

2022-03-02

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

TC-210治疗难治性间皮素阳性实体瘤：I/II期临床试验取得积极结果

2021-11-03

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Entos Pharmaceuticals已获进行COVID-19 DNA疫苗I期临床试验的资金支持

2021-02-23

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Brilacidin治疗COVID-19的II期临床试验，计划于下周开始

2021-04-10

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

中国艾滋病疫苗或明年开启III期临床试验，有望突破HIV困局

2020-12-31

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

强生新冠疫苗进入III期临床试验，大选前疫苗出炉有望吗？

2021-02-26

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

FDA允许开展Silmitasertib治疗COVID-19患者的II期临床试验

2020-11-18

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

NEJM：每日一次Relugolix联合疗法治疗子宫肌瘤的III期临床试验

2021-12-27

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

CheckMate-743是且**证明一线免疫治疗能够改善恶性胸膜间皮瘤患者生存获益的III期临床试验

2021-04-03

科室
- - 订阅+
  - 更多科室
工具
服务